• Waters entered a collaboration with Quest Diagnostics to expand US access to its FDA-cleared Onclarity at-home HPV self-collection kit.
• Starting in 2027, Quest will offer access through clinician, health plan and consumer channels.
• Patients can mail samples to Quest or drop them at approximately 2,000 patient service centers nationwide for laboratory processing.
• The collaboration leverages Quest's reach to one in three American adults annually.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waters Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610200800PR_NEWS_USPR_____NY76120) on October 20, 2026, and is solely responsible for the information contained therein.